Natera, Inc. (NASDAQ:NTRA) Director Sells $606,440.00 in Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) Director Gail Boxer Marcus sold 4,000 shares of the stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $151.61, for a total transaction of $606,440.00. Following the sale, the director now owns 9,704 shares of the company's stock, valued at approximately $1,471,223.44. This represents a 29.19 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Gail Boxer Marcus also recently made the following trade(s):

• On Tuesday, April 1st, Gail Boxer Marcus sold 4,000 shares of Natera stock. The shares were sold at an average price of $140.78, for a total transaction of $563,120.00.
• On Wednesday, March 12th, Gail Boxer Marcus sold 4,000 shares of Natera stock. The shares were sold at an average price of $147.69, for a total value of $590,760.00.

Natera Stock Up 3.5 %

NTRA opened at $156.66 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The company has a market cap of $21.18 billion, a price-to-earnings ratio of -89.01 and a beta of 1.80. Natera, Inc. has a one year low of $92.14 and a one year high of $183.00. The business's fifty day moving average is $146.93 and its two-hundred day moving average is $154.18.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. Analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on NTRA. Robert W. Baird boosted their target price on Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a report on Friday, February 28th. The Goldman Sachs Group boosted their price objective on shares of Natera from $160.00 to $190.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. BTIG Research restated a "buy" rating on shares of Natera in a research note on Friday, February 28th. StockNews.com upgraded shares of Natera from a "sell" rating to a "hold" rating in a research note on Wednesday, March 19th. Finally, Piper Sandler raised their price objective on shares of Natera from $200.00 to $205.00 and gave the company an "overweight" rating in a research report on Tuesday, March 4th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $175.76.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Wilmington Savings Fund Society FSB purchased a new position in Natera during the third quarter worth $385,000. Franklin Resources Inc. raised its stake in Natera by 42.6% in the 3rd quarter. Franklin Resources Inc. now owns 1,099,335 shares of the medical research company's stock valued at $144,958,000 after purchasing an additional 328,375 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in Natera by 2.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,012,498 shares of the medical research company's stock valued at $128,537,000 after purchasing an additional 28,751 shares in the last quarter. Versant Capital Management Inc boosted its stake in shares of Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock worth $34,000 after purchasing an additional 166 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Natera by 49.1% during the fourth quarter. GAMMA Investing LLC now owns 641 shares of the medical research company's stock worth $101,000 after buying an additional 211 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.